Outcome of Donor Lymphocyte Infusion after T Cell-depleted Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndromes

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 4, 2013, Pages 562-568

  Krishnamurthy, Pramila ^a   Potter, Victoria T ^a   Barber, Linda D ^a   Kulasekararaj, Austin G ^a   Lim, Zi Yi ^a   Pearce, Rachel M ^b   de Lavallade, Hugues ^a   Kenyon, Michelle ^a   Ireland, Robin M ^a   Marsh, Judith C W ^a   Devereux, Stephen ^a   Pagliuca, Antonio ^a   Mufti, Ghulam J ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b British Society of Bone Marrow Transplantation   (United Kingdom)

Author keywords

Myeloid cancer; Reduced intensity conditioning; T cell depletion

Indexed keywords

ALEMTUZUMAB; AMSACRINE; BUSULFAN; CYCLOSPORIN; CYTARABINE; FLUDARABINE; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CONFIDENCE INTERVAL; CYTOMEGALOVIRUS INFECTION; DONOR LYMPHOCYTE INFUSION; DRUG DOSE TITRATION; EVENT FREE SURVIVAL; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; REDUCED INTENSITY CONDITIONING; SEPSIS; T CELL DEPLETION; THERAPY EFFECT; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTILYMPHOCYTE SERUM; ANTINEOPLASTIC AGENTS; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RECURRENCE; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84875501708     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.12.013     Document Type: Article

References (40)

1. Koreth J., Schlenk R., Kopecky K.J., et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009, 301:2349-2361.
2. Oliansky D.M., Antin J.H., Bennett J.M., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biol Blood Marrow Transplant 2009, 15:137-172.
3. Valcarcel D., Martino R. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia. Curr Opin Oncol 2007, 19:660-666.
4. Aoudjhane M., Labopin M., Gorin N.C., et al. Comparative outcome of reduced-intensity and myeloablative conditioning regimens in HLA-identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT). Leukemia 2005, 19:2304-2312.
5. Ringden O., Labopin M., Ehninger G., et al. Reduced-intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 2009, 27:4570-4577.
6. Ho A.Y., Pagliuca A., Kenyon M., et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 2004, 104:1616-1623.
7. Tauro S., Craddock C., Peggs K., et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005, 23:9387-9393.
8. Soiffer R.J., Lerademacher J., Ho V., et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011, 117:6963-6970.
9. Ho V.T., Soiffer R.J. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001, 98:3192-3204.
10. Morris E.C., Rebello P., Thomson K.J., et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Blood 2003, 102:404-406.
11. Poire X., van Besien K. Alemtuzumab in allogeneic hematopoetic stem cell transplantation. Expert Opin Biol Ther 2011, 11:1099-1111.
12. Matthews K., Lim Z., Pearce L., et al. Rapid recovery of lymphocyte subsets is not associated with protection from relapse of myelodysplastic syndromes and acute myeloid leukaemia after haematopoietic stem cell transplantation using a reduced-intensity conditioning regimen and alemtuzumab. Br J Haematol 2010, 149:879-889.
13. Marks D.I., Lush R., Cavenagh J., et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2002, 100:3108-3114.
14. Roddie C., Peggs K.S. Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. Expert Opin Biol Ther 2011, 11:473-487.
15. Mohty M., Avinens O., Faucher C., et al. Predictive factors and impact of full donor T-cell chimerism after reduced-intensity conditioning allogeneic stem cell transplantation. Haematologica 2007, 92:1004-1006.
16. Shaw B.E., Byrne J.L., Das-Gupta E., et al. The impact of chimerism patterns and predonor leukocyte infusion lymphopenia on survival following T cell-depleted reduced-intensity conditioned transplants. Biol Blood Marrow Transplant 2007, 13:550-559.
17. Lim Z.Y., Pearce L., Ho A.Y., et al. Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes. Br J Haematol 2007, 138:517-526.
18. Collins R.H., Shpilberg O., Drobyski W.R., et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997, 15:433-444.
19. Levine J.E., Braun T., Penza S.L., et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 2002, 20:405-412.
20. Schmid C., Labopin M., Nagler A., et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 2007, 25:4938-4945.
21. Swerdlow S.H., Campo E., Harris N.L., et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, International Agency for Research on Cancer, Lyon, France. 4th ed.
22. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
23. Grimwade D., Hills R.K., Moorman A.V., et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010, 116:354-365.
24. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease, I: Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005, 11:945-956.
25. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
26. Fine J.P., Gray R.J. A proportional hazards model for the subdistribution of a competing risk. JASA 1999, 94:496-509.
27. Chakraverty R., Peggs K., Chopra R., et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002, 99:1071-1078.
28. Martino R., Iacobelli S., Brand R., et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006, 108:836-846.
29. van Besien K., Dew A., Lin S., et al. Patterns and kinetics of T-cell chimerism after allotransplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma 2009, 50:1809-1817.
30. Lim Z.Y., Ho A.Y., Ingram W., et al. Outcomes of alemtuzumab-based reduced-intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. Br J Haematol 2006, 135:201-209.
31. Mackinnon S., Barnett L., Heller G., et al. Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia. Blood 1994, 83:3409-3416.
32. Peggs K.S., Kayani I., Edwards N., et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. J Clinl Oncol 2011, 29:971-978.
33. Thomson K.J., Morris E.C., Milligan D., et al. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol 2010, 28:3695-3700.
34. Sairafi D., Remberger M., Uhlin M., et al. Leukemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions. Biol Blood Marrow Transplant 2010, 16:1728-1737.
35. Chakrabarti S., Mackinnon S., Chopra R., et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002, 99:4357-4363.
36. Matthews K., Lim Z., Afzali B., et al. Imbalance of effector and regulatory CD4 T cells is associated with graft-versus-host disease after hematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab. Haematologica 2009, 94:956-966.
37. Miller J.S., Warren E.H., van den Brink M.R., et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: graft-versus-tumor/leukemia reaction. Biol Blood Marrow Transplant 2010, 16:565-586.
38. + T cells. Blood 2010, 115:4923-4933.
39. Kloosterboer F.M., van Luxemburg-Heijs S.A., van Soest R.A., et al. Minor histocompatibility antigen-specific T cells with multiple distinct specificities can be isolated by direct cloning of IFNγ-secreting T cells from patients with relapsed leukemia responding to donor lymphocyte infusion. Leukemia 2005, 19:83-90.
40. Kloosterboer F.M., van Luxemburg-Heijs S.A., van Soest R.A., et al. Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1- and HA-2-specific T cells. Leukemia 2004, 18:798-808.